Singhal, Anupriya
Li, Bob T. http://orcid.org/0000-0001-6661-8733
O’Reilly, Eileen M. http://orcid.org/0000-0002-8076-9199
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P50 CA257881-01A1, K12 CA184746, P30 CA008748, P50 CA257881-01A1, P30 CA008748)
Article History
Received: 4 January 2024
Accepted: 4 March 2024
First Online: 18 April 2024
Competing interests
: E.O.R. has received institutional research funding from Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Revolution Medicine. Consulting/DSMB: Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus, Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) and Servier (Spouse). B.T.L. serves as an uncompensated advisor and consultant to Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Daiichi Sankyo, Genentech and Lilly. B.T.L. has received research grants to his institution from Amgen, AstraZeneca, Bolt Biotherapeutics, Daiichi Sankyo, Genentech, Jiangsu Hengrui Pharmaceuticals, Revolution Medicine, and Lilly. B.T.L. received academic travel support from Amgen. B.T.L. is an inventor on two institutional patents at MSK (US62/685,057, US62/514,661) and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. A.S. declares no competing interests.